ArriVent BioPharma, Inc. (AVBP)
NASDAQ: AVBP · Real-Time Price · USD
20.92
+0.10 (0.48%)
Apr 28, 2025, 4:00 PM EDT - Market closed
ArriVent BioPharma Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for ArriVent BioPharma stock have an average target of 39, with a low estimate of 36 and a high estimate of 45. The average target predicts an increase of 86.42% from the current stock price of 20.92.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 20, 2025.
Analyst Ratings
The average analyst rating for ArriVent BioPharma stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 5 | 5 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B. Riley Securities | B. Riley Securities | Strong Buy Initiates $37 | Strong Buy | Initiates | $37 | +76.86% | Mar 20, 2025 |
| Guggenheim | Guggenheim | Strong Buy Initiates $45 | Strong Buy | Initiates | $45 | +115.11% | Mar 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $39 | Strong Buy | Reiterates | $39 | +86.42% | Mar 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $36 → $39 | Strong Buy | Maintains | $36 → $39 | +86.42% | Jan 22, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $36 | Strong Buy | Reiterates | $36 | +72.08% | Nov 15, 2024 |
Financial Forecast
Revenue This Year
291.93M
from 178.96M
Increased by 63.13%
Revenue Next Year
n/a
from 291.93M
EPS This Year
-2.98
from -2.56
EPS Next Year
-3.59
from -2.98
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 44.7M | 129.5M | ||
| Avg | n/a | 13.3M | 75.8M | ||
| Low | n/a | n/a | 44.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 870.8% | ||
| Avg | - | - | 468.0% | ||
| Low | - | - | 234.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.83 | -1.78 | -0.42 | ||
| Avg | -2.98 | -3.59 | -2.07 | ||
| Low | -3.89 | -4.55 | -3.45 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.